Network pharmacology analysis predicted that the PI3K/AKT signaling pathway is critical for BBEA's anti-RA activity, and molecular docking confirmed strong binding affinities between key components (e.g., Genkwanin) and core targets (SRC, AKT1). The gene discussed is SRC; the disease is rheumatoid arthritis.